1. Canada Stocks

  2. •

    Consumer Defensive

  3. •

    Food Distribution
Eastwood Bio-Medical Canada Inc.

Eastwood Bio-Medical Canada Inc.

EWOOF
Eastwood Bio-Medical Canada Inc.US flagOther OTC
0.69
USD
- -
- -
47.79MMarket Cap
Eastwood Bio-Medical Canada Inc.
EWOOF
(Other OTC)

Recent

price

0.69

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
0.01
0.01
0.02
0.01
0.01
0.01
0.02
0.01
0.01
0.02
0.01
0.01
Revenue per Share
- -
-0.01
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
- -
-0.01
-0.01
Basic EPS, GAAP
- -
0.03
- -
- -
-0.01
-0.01
- -
-0.01
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.08
0.06
0.05
0.04
0.03
0.02
0.01
- -
- -
-0.01
-0.02
Book Value per Share
- -
0.08
0.06
0.05
0.04
0.03
0.02
0.01
- -
- -
-0.01
-0.02
Tangible Book Value per Share
67
51
67
67
68
69
69
69
69
69
69
69
Basic Weighted Avg Shares
1
- -
1
- -
- -
1
1
1
1
1
1
1
Sales/Revenue/Turnover
-24.75
-109.34
-23.66
-109.39
-122.2
-76.07
-44.65
-118.59
-60.74
-9.95
-58.21
-68.94
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
- -
- -
- -
-1
-1
-1
-1
- -
-1
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-24
-112.48
-21.95
-100.98
-102.06
-115.86
-44.65
-118.67
-61.53
-11.53
-62.98
-74.09
Profit Margin (%)
- -
4
4
3
3
2
- -
- -
-1
-1
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
4
4
3
3
2
1
- -
- -
- -
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-6.77
-13.55
-16.46
-37.22
-36.29
-97.31
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jan'24
Apr'24
Jul'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
69
Market Capitalization
65
- -
66

Working Capital

FRC

•

in mil. unless spec.
Jan'24
Apr'24
Jul'24
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-201.72%
12.53%
185.79%
Free Cash Flow
-71.01%
14.75%
131.37%
Net Income, GAAP
55.83%
34.99%
264.69%
Sales/Revenue/Turnover
19.93%
13.04%
-33.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
1
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Kitwave Group plc (KITW.L)
Organto Foods Inc. (OGO.V)
Hosen Group Ltd. (5EV.SI)
Neelamalai Agro Industries Limited (NEAGI.BO)
SC Agrotech Limited (SCAGRO.BO)
Whole Foods Market, Inc. (WFM)
Business
Eastwood Bio-Medical Canada Inc. markets and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia; the company serves as the licensed distributor for the Eleotin line of formulations based on natural ingredients presented in tea or capsule forms targeting metabolic disorders including blood glucose issues, hypertension, and obesity as dietary supplements. Core products with Health Canada licenses include Eleotin A 700 for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 as a laxative; Eleotin Cal20 and Eleotin V3D for bone and teeth maintenance and development; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; Eleotin Zn330 for tissue formation and metabolism; Eleotin Bentley to promote healthy glucose levels; and Eleotin LBM for hypertension relief. Incorporated in 2010 and headquartered at 1130-4871 Shell Road, Richmond, British Columbia, Canada, the company operates primarily in the natural health supplements industry with a focus on North American and Asian markets. In recent developments, Eastwood Bio-Medical Canada Inc. enters into a loan extension agreement with affiliate Eastwood Bio-Medical Research Inc., reflecting ongoing financial arrangements amid trailing twelve-month revenue of CAD715.79k and net income of -CAD442.85k as of the latest reports.